Novel antagonists of cxcr3-binding cxc chemokines
CA 2489298 C · Owner: Kosco-Vilbois, Marie · Inventors: Proudfoot, Amanda; Kosco-Vilbois, Marie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel antagonists of CXCR3 -binding CXC chemokines and in particular of human , CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can be used to block the activity of CXCR3-binding CXC chemokines on CXCR3 -expressing cells thereby providing , therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration such as graft rejection and , autoimmune diseases and of diseases needing an increase of vascularization …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 3, 2003 and granted September 11, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 3, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 3, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.